{"id":"https://openalex.org/W113520239","doi":null,"title":"Aldosterone synthase inhibitors: pharmacological and clinical aspects.","display_name":"Aldosterone synthase inhibitors: pharmacological and clinical aspects.","publication_year":2009,"publication_date":"2009-04-01","ids":{"openalex":"https://openalex.org/W113520239","mag":"113520239","pmid":"https://pubmed.ncbi.nlm.nih.gov/19337952"},"language":"en","primary_location":{"id":"pmid:19337952","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19337952","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025200078","display_name":"Pieter M. Jansen","orcid":"https://orcid.org/0000-0003-4416-0287","observed_orcids":["https://orcid.org/0000-0003-4416-0287"]},"institutions":[{"id":"https://openalex.org/I2801952686","display_name":"Erasmus MC","ror":"https://ror.org/018906e22","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Pieter M Jansen","raw_affiliation_strings":["Erasmus MC, Division of Pharmacology, Vascular & Metabolic Diseases, Department of Internal Medicine, Dr Molewaterplein 50, 3015 GE Rotterdam, the Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Erasmus MC, Division of Pharmacology, Vascular & Metabolic Diseases, Department of Internal Medicine, Dr Molewaterplein 50, 3015 GE Rotterdam, the Netherlands","institution_ids":["https://openalex.org/I2801952686"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108999303","display_name":"Anton H. van den Meiracker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anton H van den Meiracker","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5111880960","display_name":"AH Jan Danser","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A H Jan Danser","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.175,"has_fulltext":false,"cited_by_count":22,"citation_normalized_percentile":{"value":0.86951781,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":97},"biblio":{"volume":"10","issue":"4","first_page":"319","last_page":"26"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11839","display_name":"Hormonal Regulation and Hypertension","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11839","display_name":"Hormonal Regulation and Hypertension","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11001","display_name":"Renin-Angiotensin System Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12421","display_name":"Adrenal Hormones and Disorders","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/aldosterone-synthase-inhibitors","display_name":"aldosterone synthase inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/aldosterone","display_name":"aldosterone","score":0.8429999947547913},{"id":"https://openalex.org/keywords/mineralocorticoid-receptor-antagonism","display_name":"mineralocorticoid receptor antagonism","score":0.9470000267028809},{"id":"https://openalex.org/keywords/heart-failure","display_name":"heart failure","score":0.7739999890327454},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cardiovascular-disease","display_name":"cardiovascular disease","score":0.9670000076293945},{"id":"https://openalex.org/keywords/enzyme-specificity","display_name":"enzyme specificity","score":0.48500001430511475},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.8849999904632568}],"concepts":[{"id":"https://openalex.org/C2780249997","wikidata":"https://www.wikidata.org/wiki/Q14904983","display_name":"Aldosterone synthase","level":4,"score":0.9200583696365356},{"id":"https://openalex.org/C2778525890","wikidata":"https://www.wikidata.org/wiki/Q184564","display_name":"Aldosterone","level":2,"score":0.9188500642776489},{"id":"https://openalex.org/C189135053","wikidata":"https://www.wikidata.org/wiki/Q3454531","display_name":"Mineralocorticoid receptor","level":3,"score":0.8911104202270508},{"id":"https://openalex.org/C2776069600","wikidata":"https://www.wikidata.org/wiki/Q422519","display_name":"Mineralocorticoid","level":3,"score":0.6573193073272705},{"id":"https://openalex.org/C2777383412","wikidata":"https://www.wikidata.org/wiki/Q4770891","display_name":"Antagonism","level":3,"score":0.6145410537719727},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.5427991151809692},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5335578918457031},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5161105394363403},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5075513124465942},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4916577935218811},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.4397081136703491},{"id":"https://openalex.org/C198710026","wikidata":"https://www.wikidata.org/wiki/Q898218","display_name":"Renin\u2013angiotensin system","level":3,"score":0.18903449177742004},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.12306609749794006}],"mesh":[{"descriptor_ui":"D000302","descriptor_name":"Adrenal Cortex","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D000302","descriptor_name":"Adrenal Cortex","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D000450","descriptor_name":"Aldosterone","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D000451","descriptor_name":"Mineralocorticoid Receptor Antagonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000451","descriptor_name":"Mineralocorticoid Receptor Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000451","descriptor_name":"Mineralocorticoid Receptor Antagonists","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002784","descriptor_name":"Cholesterol","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018161","descriptor_name":"Receptors, Mineralocorticoid","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D019405","descriptor_name":"Cytochrome P-450 CYP11B2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D019405","descriptor_name":"Cytochrome P-450 CYP11B2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":4,"locations":[{"id":"pmid:19337952","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19337952","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in investigational drugs (London, England : 2000)","raw_type":"Journal Article"},{"id":"pmh:eur:oai:pure.eur.nl:publications/a81c069b-c60d-4446-829e-e87b89d6d718","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/a81c069b-c60d-4446-829e-e87b89d6d718","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Current Opinion in Investigational Drugs, 10(4), 319 - 326. Current Drugs Ltd.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.eur.nl:openaire_cris_publications/a81c069b-c60d-4446-829e-e87b89d6d718","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/a81c069b-c60d-4446-829e-e87b89d6d718","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Jansen, P, van den Meiracker, T & Danser, J 2009, 'Aldosterone synthase inhibitors: Pharmacological and clinical aspects', Current Opinion in Investigational Drugs, vol. 10, no. 4, pp. 319-326.","raw_type":"info:eu-repo/semantics/article"},{"id":"mag:113520239","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19337952","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9789000153541565,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7162075523","https://openalex.org/W2383007280","https://openalex.org/W2105712276","https://openalex.org/W4390115139","https://openalex.org/W7161767742","https://openalex.org/W2065371089","https://openalex.org/W2112800169","https://openalex.org/W7118556611","https://openalex.org/W3107782462","https://openalex.org/W7124242188"],"abstract_inverted_index":{"Aldosterone":[0],"plays":[1],"an":[2,32],"important":[3],"pathophysiological":[4],"role":[5],"in":[6,17,34,41],"cardiovascular":[7],"disease,":[8],"and":[9,23,79,85,93],"aldosterone":[10,26,36,51,65,74,101],"(mineralocorticoid)":[11],"receptor":[12,27,60],"antagonism":[13,28],"has":[14],"been":[15],"used":[16],"the":[18,48,59,80],"treatment":[19],"of":[20,50,64],"heart":[21],"failure":[22],"hypertension.":[24],"However,":[25,71],"is":[29,89],"associated":[30],"with":[31],"increase":[33],"plasma":[35],"levels,":[37],"which":[38],"may":[39,53],"result":[40],"non-mineralocorticoid":[42],"receptor-mediated":[43],"(non-genomic)":[44],"adverse":[45],"effects.":[46],"Therefore,":[47],"inhibition":[49],"synthesis":[52],"be":[54,105],"preferable":[55],"to":[56,98],"blockade":[57],"at":[58],"level.":[61],"Direct":[62],"inhibitors":[63,103],"synthase":[66,75,102],"are":[67,96],"currently":[68],"under":[69],"development.":[70],"specificity":[72],"for":[73,82],"remains":[76],"a":[77],"challenge,":[78],"search":[81],"more":[83,86],"potent":[84],"selective":[87],"compounds":[88],"ongoing.":[90],"Experimental":[91],"animal":[92],"human":[94],"studies":[95],"required":[97],"establish":[99],"whether":[100],"will":[104],"successful":[106],"as":[107],"therapeutic":[108],"agents.":[109]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}